Harry Iland
Professor
Medicine
University of Sydney
Australia
Biography
Dr. Harry Iland is a Professor of Medicine at Central Clinical School
Research Interest
His main interests have encompassed molecular abnormalities in haematological malignancies, and he established one of the earliest molecular diagnostic laboratories for haematological malignancy in Australia. In the last few years he has been responsible for the Australasian Leukaemia and Lymphoma Group's clinical trial program in acute promyelocytic leukaemia (APL), and has combined this with an active laboratory program in the molecular analysis of APL cells. His laboratory has also established molecular assays relevant for patients with idiopathic hypereosinophilic syndrome / chronic eosinophilic leukaemia.
Publications
-
He, S., Busfield, S., Ritchie, D., Hertzberg, M., Durrant, S., Lewis, I., Marlton, P., McLachlan, A., Kerridge, I., Bradstock, K., Iland, H., et al (2015). A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leukemia & Lymphoma, 56(5), 1406-1415
-
Mohamed, M., Iland, H., Sharma, S., Supple, S. (2016). Atypical presentation of therapy-related acute promyelocytic leukaemia with marrow fibrosis. Pathology, 48(3), 286-288.
-
Mantha, S., Goldman, D., Devlin, S., Lee, J., Zannino, D., Collins, M., Douer, D., Iland, H., Litzow, M., Stein, E., et al (2017). Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 129(13), 1763-1767
